ADAPY

0.03003.23%
SA

Stephan A. Grupp

Member of the Scientific Advisory Board

Dr. Stephan A. Grupp, M.D., Ph.D., is Member of Scientific Advisory Board of Estrella Immunopharma, Inc. He serves as Member of Scientific Advisory Board GlobeNewswire at Allogene Therapeutics, Inc. since July 2020. He is Member of Scientific Advisory Board at Adaptimmune Therapeutics plc. He serves as Member of Scientific Advisory Board of Cellular Biomedicine Group, Inc., since December 18, 2018. Dr. Grupp serves as Member of the Advisory Board at TCR2 Therapeutics Inc. He has been Member of Clinical Advisory Board of Cellectis S.A. since September 19, 2018. Dr. Grupp has been Chief of Section - Cellular Therapy and Transplant in Oncology Division at The Children's Hospital of Philadelphia since June 1, 2017. Dr. Grupp has researched and led groundbreaking clinical trials of an innovative T cell therapy for children with acute lymphoblastic leukemia (ALL). He serves as Medical Director of the Stem Cell Laboratory at CHOP. He has been an attending physician and oncology researcher at CHOP since 1996. Reflecting the translational focus of his work, he also developed and led clinical trials that established tandem stem cell transplantation (two separate transplant procedures) as a standard of care for children with high-risk neuroblastoma. He helped to develop and lead clinical trials that resulted in FDA approval of a new treatment for veno-occlusive disease, a deadly complication of stem cell transplantation. In addition, he led the pediatric hematology/oncology fellowship training program at CHOP for almost a decade. He served as a Member of Scientific Advisory Board of Eureka Therapeutics, Inc. since July 2018. His outstanding contribution to oncology is in the clinical development of chimeric antigen receptor (CAR) T cell therapy for relapsed and refractory ALL in children and young adults. He is the Director of the Cancer Immunotherapy Program, Director of Translational Research for the Center for Childhood Cancer Research. He did many of the preclinical in vivo studies and then developed the first pediatric trial and treated the first pediatric patient at CHOP with CAR T cell therapy in 2012. He is a Professor of Pediatrics in Penn's Perelman School of Medicine. He completed his clinical training in pediatrics and pediatric hematology/oncology at Boston Children's Hospital, Dana Farber Cancer Institute and Harvard Medical School, performing postdoctoral research in immunology at Harvard. He joined the University of Pennsylvania medical faculty in 1996. Dr. Grupp earned his MD and a PhD in Immunology from the University of Cincinnati.

Positions